New therapeutic options for refractory neurogenic detrusor overactivity;Nuove opzioni terapeutiche nell'iperattività detrusoriale refrattaria su base neurogena

Minerva Urologica e Nefrologica

Volumn 56, Issue 1, 2004, Pages 79-87

  Giannantoni, A ^a,d   Mearini, E ^a   Di Stasi, S M ^b   Costantini, E ^a   Zucchi, A ^a   Mearini, L ^a   Fornetti, P ^a   Del Zingaro, M ^a   Navarra, P ^c   Porena, M ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d POLICLINICO MONTELUCE   (Italy)

Author keywords

Botulinum toxin; Neurogenic detrusor overactivity; Resiniferatoxin

Indexed keywords

BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; RESINIFERATOXIN;

ARTICLE; BLADDER CATHETERIZATION; DETRUSOR MUSCLE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROGENIC DETRUSOR OVERACTIVITY; OVERACTIVE BLADDER; SIDE EFFECT; SPINAL CORD INJURY; TREATMENT OUTCOME; URINE INCONTINENCE; URODYNAMICS; VALIDATION PROCESS;

ADMINISTRATION, INTRAVESICAL; BOTULINUM TOXIN TYPE A; DITERPENES; FEMALE; HUMANS; MALE; MUSCLE, SMOOTH; NEUROMUSCULAR AGENTS; NEUROTOXINS; URINARY BLADDER, NEUROGENIC;

EID: 3142748992     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Yoshimura N, Chancellor MB. Current and future pharmacological treatment for overactive bladder. J Urol 2002;168:1897-913.
2. Chancellor MB, de Groat WC. Intravesical capsaicin and resiniferatoxin: spicing up the ways to treat the overactive bladder. J Urol 1999;162:3-11.
3. Duk-Yoon K, Chancellor MB. Intravesical neuromodulatory drugs: capsaicin and resiniferatoxin to treat the overactive bladder. J Endourol 2000;14:97-103.
4. Di Stasi SM, Giannantoni A, Vespasiani G, Navarra P, Capelli G, Massoud R et al. Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anti-cholinegic regimens. J Urol 2001;165:491-8.
5. Maggi CA, Barbanti G, Santicioli P, Beneforti P, Misuri D, Meli A et al. Cystometric evidence that capsaicin-sensitive nerves modulate the afferent branch of the micturition reflex in humans. J Urol 1989;142:150-4.
6. Giannantoni A, Di Stasi SM, Stephen RL, Navarra P, Scivoletto G, Mearini E et al. Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomized study. J Urol 2002;167:1710-4.
7. Lazzeri M, Spinelli M, Beneforti P, Zanollo A, Turini D. Intravesical resiniferatoxin for the treatment of detrusor hyperreflexia refractory to capsaicin in patients with chronic spinal cord disease. Scand J Urol Nephrol 1998;32:331-4.
8. Silva C, Rio ME, Cruz F. Desensitization of bladder sensory fibers by intravesical resiniferatoxin, a capsaicin analog: long-term results for the treatment of detrusor hyperreflexia. Eur Urol 2000;38:444-52.
9. Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results J Urol 2000;164(3 Pt 1):692-7.
10. Schulte-Baukloh H, Michael T, Sturzebecher B, Knispel HH. Botulinum-a toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol 2003;44:139-43.
11. Stöhrer M, Goepel M, Kondo A, Kramer G, Madersbacher H, Millard R versus The standardization of terminology in neurogenic lower urinary tract dysfunction. Neurourol Urodyn 1999;18:139-58.
12. Cuzick J. A Wilcoxon-type test for trend. Stat Med 1985:4:87-90.
13. Kuo H-C. Effectiveness of intravesical resiniferatoxin for detrusor overactivity due too non spiral coral lesions refractory to anticholinergic treatment. J Urol 2003;170: 835-9.
14. Yoshimura N. Bladder afferent pathway and spinal cord injury: possible mechanisms inducing hyperreflexia of the urinary bladder. Prog Neurobiol 1999;57: 583-606.
15. Silva C, Ribeiro MJ, Cruz F. The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input. J Urol 2002;168:575-9.
16. Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol 2003;44:105-74.
17. Duchen LW. Changes in motor innervation and cholinesterase localization induced by botulinum toxin in skeletal muscle of mouse: differences between fast and slow muscles. J Neurol Neurosurg Psychiatry 1970;33:40-54.